AbbVie Inc. Gross Margin

Gross Margin of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.

Highlights and Quick Summary

  • Gross Margin for the quarter ending September 29, 2021 was 69.91% (a 2.91% increase compared to previous quarter)
  • Year-over-year quarterly Gross Margin increased by 2.64%
  • Annual Gross Margin for 2020 was 69.18% (a -10.32% decrease from previous year)
  • Annual Gross Margin for 2019 was 77.14% (a 0.27% increase from previous year)
  • Annual Gross Margin for 2018 was 76.93% (a 1.38% increase from previous year)
  • Twelve month Gross Margin ending September 29, 2021 was 68.48% (a 3.32% increase compared to previous quarter)
  • Twelve month trailing Gross Margin increased by 2.21% year-over-year
Trailing Gross Margin for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
68.48% 66.28% 65.43% 67.0%
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of AbbVie Inc.

Most recent Gross Marginof ABBV including historical data for past 10 years.

Interactive Chart of Gross Margin of AbbVie Inc.

AbbVie Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 69.91% 67.93% 67.87%
2020 68.11% 60.91% 64.4% 77.47% 69.18%
2019 76.95% 77.36% 77.96% 78.36% 77.14%
2018 75.65% 77.72% 76.64% 75.71% 76.93%
2017 70.53% 76.9% 77.98% 75.28% 75.88%
2016 77.13% 76.62% 78.22% 77.02% 77.32%
2015 76.95% 80.37% 83.27% 81.31% 80.31%
2014 79.48% 78.2% 77.41% 75.89% 77.83%
2013 74.92% 76.56% 77.54% 73.37% 75.62%
2012 75.7% 77.51% 76.12% 72.3% 75.47%
2011 29.45% 100.0% 100.0% 69.02% 73.41%
2010 72.55%

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.